Valproic Acid-Based 2-Agent Oral Regimens for Patients With Advanced Solid Tumor
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The goal of this clinical research study is to find the highest tolerable dose of valproic
acid in combination with either dasatinib, erlotinib hydrochloride, lapatinib, lenalidomide,
sorafenib, or SU011248 (sunitinib malate) that can be given to patients with advanced cancer.
The safety of each combination of the study drugs will be studied as well.